Michael Jefford1,2,3,4, Andrew C Ward5, Karolina Lisy6, Karen Lacey7, Jon D Emery7,8,9, Adam W Glaser10, Hannah Cross7, Mei Krishnasamy7,8, Sue-Anne McLachlan11, Jim Bishop7. 1. Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Michael.Jefford@petermac.org. 2. Australian Cancer Survivorship Centre, a Richard Pratt legacy, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Michael.Jefford@petermac.org. 3. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. Michael.Jefford@petermac.org. 4. Department of Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett Street, Melbourne, Victoria, 8006, Australia. Michael.Jefford@petermac.org. 5. The Social Research Centre, Melbourne, Victoria, Australia. 6. Department of Cancer Experiences Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 7. Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia. 8. Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia. 9. Department of General Practice, University of Melbourne, Melbourne, Victoria, Australia. 10. Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK. 11. St Vincent's Hospital, Melbourne, Victoria, Australia.
Abstract
PURPOSE: There is a lack of robust population-based data regarding the lived experience of cancer survivors. This study assessed the quality of life (QoL) of survivors of breast, colorectal, or prostate cancer, non-Hodgkin lymphoma or melanoma 1, 3 and 5 years post-diagnosis. Associations between various demographic and disease-related factors and QoL were assessed. METHODS: A cross-sectional postal survey was undertaken. Eligible participants were identified from a population-based cancer registry. Patient-reported outcomes including QoL, symptom issues and information needs were collected using validated questionnaires. RESULTS: Difficulties with all QoL domains were more prevalent amongst cancer survivors compared with the general population, particularly difficulties with usual activities (28 vs 15%) and anxiety or depression (35 vs 22%). Symptoms such as trouble sleeping, always feeling tired, trouble concentrating and fear of cancer recurrence persisted up to 5 years post-diagnosis. Factors associated with reduced QoL included having another long-standing health condition, cancer not responding fully to treatment, not having or not being certain of having a written care plan and being female. CONCLUSIONS: Cancer survivors experience inferior QoL and cancer-related symptoms for years following diagnosis. These results support further investigation into factors that contribute to poorer survivor outcomes and enhanced identification and intervention strategies for those requiring additional support.
PURPOSE: There is a lack of robust population-based data regarding the lived experience of cancer survivors. This study assessed the quality of life (QoL) of survivors of breast, colorectal, or prostate cancer, non-Hodgkin lymphoma or melanoma 1, 3 and 5 years post-diagnosis. Associations between various demographic and disease-related factors and QoL were assessed. METHODS: A cross-sectional postal survey was undertaken. Eligible participants were identified from a population-based cancer registry. Patient-reported outcomes including QoL, symptom issues and information needs were collected using validated questionnaires. RESULTS: Difficulties with all QoL domains were more prevalent amongst cancer survivors compared with the general population, particularly difficulties with usual activities (28 vs 15%) and anxiety or depression (35 vs 22%). Symptoms such as trouble sleeping, always feeling tired, trouble concentrating and fear of cancer recurrence persisted up to 5 years post-diagnosis. Factors associated with reduced QoL included having another long-standing health condition, cancer not responding fully to treatment, not having or not being certain of having a written care plan and being female. CONCLUSIONS:Cancer survivors experience inferior QoL and cancer-related symptoms for years following diagnosis. These results support further investigation into factors that contribute to poorer survivor outcomes and enhanced identification and intervention strategies for those requiring additional support.
Entities:
Keywords:
Cancer; Cancer survivors; Patient-reported outcomes; Quality of life; Supportive care; Survivorship
Authors: Mary Ann Burg; Gail Adorno; Ellen D S Lopez; Victoria Loerzel; Kevin Stein; Cara Wallace; Dinghy Kristine B Sharma Journal: Cancer Date: 2015-01-12 Impact factor: 6.860
Authors: Elizabeth G Eakin; Danny R Youlden; Peter D Baade; Sheleigh P Lawler; Marina M Reeves; Jane S Heyworth; Lin Fritschi Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-10 Impact factor: 4.254
Authors: Katharine Hodgkinson; Phyllis Butow; Glenn E Hunt; Susan Pendlebury; Kim M Hobbs; Gerard Wain Journal: Support Care Cancer Date: 2006-11-21 Impact factor: 3.603
Authors: Karen Lacey; James F Bishop; Hannah L Cross; Patty Chondros; Georgios Lyratzopoulos; Jon D Emery Journal: Med J Aust Date: 2016-07-18 Impact factor: 7.738
Authors: Amy Downing; Eva J A Morris; Mike Richards; Jessica Corner; Penny Wright; David Sebag-Montefiore; Paul Finan; Paul Kind; Charlotte Wood; Sarah Lawton; Richard Feltbower; Richard Wagland; Sally Vernon; James Thomas; Adam W Glaser Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: Adam W Glaser; Lorna K Fraser; Jessica Corner; Richard Feltbower; Eva J A Morris; Greg Hartwell; Mike Richards; Richard Wagland Journal: BMJ Open Date: 2013-04-10 Impact factor: 2.692
Authors: Hanne C Lie; Corina S Rueegg; Sophie D Fosså; Jon H Loge; Ellen Ruud; Cecilie E Kiserud Journal: J Cancer Surviv Date: 2019-04-16 Impact factor: 4.442
Authors: Helena C Frawley; Kuan-Yin Lin; Catherine L Granger; Rosemary Higgins; Michael Butler; Linda Denehy Journal: Support Care Cancer Date: 2019-06-27 Impact factor: 3.603
Authors: Marieke van Leeuwen; Jacobien M Kieffer; Teresa E Young; Maria Antonietta Annunziata; Volker Arndt; Juan Ignacio Arraras; Didier Autran; Hira Bani Hani; Manas Chakrabarti; Olivier Chinot; Juhee Cho; Rene Aloisio da Costa Vieira; Anne-Sophie Darlington; Philip R Debruyne; Linda Dirven; Daniela Doege; Yannick Eller; Martin Eichler; Nanna Fridriksdottir; Ioannis Gioulbasanis; Eva Hammerlid; Mieke van Hemelrijck; Silke Hermann; Olga Husson; Michael Jefford; Christoffer Johansen; Trille Kristina Kjaer; Meropi Kontogianni; Pernilla Lagergren; Emma Lidington; Karolina Lisy; Ofir Morag; Andy Nordin; Amal S H Al Omari; Andrea Pace; Silvia De Padova; Duska Petranovia; Monica Pinto; John Ramage; Elke Rammant; Jaap Reijneveld; Samantha Serpentini; Sam Sodergren; Vassilios Vassiliou; Irma Verdonck-de Leeuw; Ingvild Vistad; Teresa Young; Neil K Aaronson; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2022-01-27 Impact factor: 4.442
Authors: Lynn Batehup; Heather Gage; Peter Williams; Alison Richardson; Katerina Porter; Peter Simmonds; Elizabeth Lowson; Lynne Dodson; Nicola Davies; Richard Wagland; Jane Winter; Andrew Turner; Jessica Corner Journal: Eur J Cancer Care (Engl) Date: 2021-08-22 Impact factor: 2.328
Authors: Soohyun Hwang; Burcu Bozkurt; Tamara Huson; Sarah Asad; Lauren Richardson; Joseph Amarachi Ogbansiegbe; Laura Viera; Caroline Buse; Ted A James; Deborah K Mayer; Lawrence N Shulman; Sarah A Birken Journal: JCO Oncol Pract Date: 2021-10-04